Advancing Drug Development in AL Amyloidosis: Capitalizing Natural History and Assessing Endpoints
About the Meeting
Come join the Amyloidosis Forum as we convene at FDA to break down the barriers to drug development in AL amyloidosis. Take part in the conversation as we discuss the challenges, obstacles and new and improved pathways towards developing treatments for AL amyloidosis. This is a unique opportunity to innovate with leaders in the amyloidosis field and contribute to shaping a better future for patients whose lives have been affected by this complex disease.
The Amyloidosis Forum
The Amyloidosis Forum is an initiative created by the Amyloidosis Research Consortium (ARC). The overarching goal of the forum is to leverage expertise and resources from all stakeholders to advance rigorous science to bridge the gaps in drug discovery and development in AL amyloidosis. For more information contact: arc@arci.org, or call 617-467-5170
Who should attend
-
Regulatory -
Physicians -
Patients & Caregivers -
Researchers -
Industry
The meeting aims to engage the active participation of representatives from all areas.
The Amyloidosis Research Consortium
The Amyloidosis Research Consortium (ARC) is a nonprofit organization focused on accelerating the development of and access to new and innovative therapies, and improving quality of life for all patients with amyloidosis. ARC brings together all the stakeholders involved in drug development to collaborate on breaking down the barriers that are slowing down the development of the most promising treatments for patients. These stakeholders include patients, researchers, clinicians, pharmaceutical companies, regulators, policy makers and payers. This innovative model has resulted in the Amyloidosis Forum, ARC’s formalized Public Private Partnership with FDA.
Learn more about ARC: www.arci.org